Associated Genetic Biomarkers
APOBEC3G is altered in 1.03% of all cancers with conventional glioblastoma multiforme, cutaneous melanoma, adenocarcinoma of unknown primary, anaplastic oligodendroglioma, and basal cell carcinoma having the greatest prevalence of alterations .
The most common alterations in APOBEC3G are APOBEC3G Mutation (0.96%), APOBEC3G A109S (0.09%), APOBEC3G D128N (0.07%), APOBEC3G D317N (0.07%), and APOBEC3G D370A (0.09%) .
APOBEC3G status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain APOBEC3G status as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Trials with APOBEC3G status in the inclusion eligibility criteria most commonly target cancer and malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is APOBEC3G Mutation .
Ceralasertib, nivolumab, and olaparib are the most frequent therapies in trials with APOBEC3G as an inclusion criteria .
Significance of APOBEC3G in Diseases
Malignant Solid Tumor +
APOBEC3G is altered in 1.11% of malignant solid tumor patients .
APOBEC3G is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3G status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
Central Nervous System Neoplasm +
APOBEC3G is altered in 0.71% of central nervous system neoplasm patients .
APOBEC3G is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3G status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
APOBEC3G is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3G status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.